PMID: 9449255Feb 4, 1998Paper

Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice

Antimicrobial Agents and Chemotherapy
T FukuokaS Kuwahara

Abstract

The efficacy of CS-834, a novel oral carbapenem, was assessed by using a murine model of pneumonia caused by penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and was compared with those of oral cephems, i.e., cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil. Intranasal inoculation of 10(6) CFU of penicillin-susceptible or penicillin-resistant S. pneumoniae in the exponential growth phase induced pneumonia and bacteremia in ddY mice within 48 h. For the treatment of infections caused by the penicillin-susceptible strain the antibiotics were administered orally at 0.4, 2, and 10 mg/kg of body weight twice daily for 2 days beginning at 24 h after bacterial inoculation, and for the treatment of infections caused by a penicillin-resistant strain the antibiotics were administered at 2, 10, and 50 mg/kg twice daily for 2 days beginning at 24 h after bacterial inoculation. Among the antibiotics tested, CS-834 exhibited the most potent efficacy against both types of strains. Against infections caused by penicillin-susceptible S. pneumoniae, CS-834 at all doses significantly reduced the numbers of viable cells in both the lungs and blood. Cefpodoxime proxetil at all doses and cefteram pivox...Continue Reading

References

Aug 21, 1992·Science·H C Neu
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P C Appelbaum
Oct 1, 1989·Antimicrobial Agents and Chemotherapy·H C NeuN X Chin
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·A TamuraS Mitsuhashi
Jul 1, 1987·Antimicrobial Agents and Chemotherapy·Y UtsuiS Mitsuhashi
Sep 5, 1985·The New England Journal of Medicine·C FeldmanH J Koornhof
Jul 31, 1982·Lancet·J T MacfarlaneA D Macrae

❮ Previous
Next ❯

Citations

Nov 4, 2000·Expert Opinion on Investigational Drugs·M Cazzola
Jul 29, 2005·Antimicrobial Agents and Chemotherapy·Tetsufumi KogaSyogo Kuwahara
Feb 25, 2003·American Journal of Respiratory and Critical Care Medicine·Sumito InoueHitonobu Tomoike

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.